MannKind’s (MNKD) “Overweight” Rating Reiterated at Cantor Fitzgerald

Posted by Brenda Bartman on Oct 20th, 2026

MannKind (NASDAQ:MNKD – Get Free Report)‘s stock had its “overweight” rating restated by stock analysts at Cantor Fitzgerald in a research report issued on Tuesday, Benzinga reports. They currently have a $8.00 price objective on the biopharmaceutical company’s stock. Cantor Fitzgerald‘s target price indicates a potential upside of 158.90% from the company’s current price.

Several other research analysts have also issued reports on MNKD. Zacks Research upgraded MannKind from a “strong sell” rating to a “hold” rating in a research report on Monday, October 5th. Wells Fargo & Company reduced their target price on MannKind from $14.00 to $13.00 and set an “overweight” rating on the stock in a report on Thursday, August 6th. Truist Financial reduced their target price on MannKind from $6.00 to $5.00 and set a “buy” rating on the stock in a report on Wednesday, October 7th. Weiss Ratings reiterated a “sell (d)” rating on shares of MannKind in a report on Friday, October 2nd. Finally, HC Wainwright reiterated a “buy” rating on shares of MannKind in a report on Thursday, July 23rd. Eight research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, MannKind currently has an average rating of “Moderate Buy” and a consensus price target of $8.08.

Get Our Latest Research Report on MannKind

MannKind Stock Down 0.3%

NASDAQ:MNKD opened at $3.09 on Tuesday. MannKind has a 12-month low of $2.23 and a 12-month high of $6.51. The firm has a market capitalization of $993.56 million, a P/E ratio of -23.62 and a beta of 1.09. The stock’s fifty day simple moving average is $3.70 and its 200-day simple moving average is $3.59.

MannKind (NASDAQ:MNKD – Get Free Report) last posted its quarterly earnings results on Wednesday, August 5th. The biopharmaceutical company reported ($0.01) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.01). The company had revenue of $109.37 million during the quarter, compared to the consensus estimate of $108.08 million. During the same quarter in the prior year, the business earned $0.05 earnings per share. The firm’s revenue for the quarter was up 43.0% on a year-over-year basis. As a group, equities research analysts expect that MannKind will post -0.20 earnings per share for the current year.

Insiders Place Their Bets

In other MannKind news, Director Steven Binder sold 39,051 shares of MannKind stock in a transaction dated Friday, August 7th. The stock was sold at an average price of $4.06, for a total transaction of $158,547.06. Following the transaction, the director directly owned 785,867 shares in the company, valued at approximately $3,190,620.02. The trade was a 4.73% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders sold 111,660 shares of company stock worth $414,881 in the last 90 days. Insiders own 2.60% of the company’s stock.

Institutional Trading of MannKind

A number of institutional investors have recently modified their holdings of the company. Waverly Advisors LLC lifted its holdings in shares of MannKind by 43.0% in the second quarter. Waverly Advisors LLC now owns 24,948 shares of the biopharmaceutical company’s stock valued at $106,000 after purchasing an additional 7,498 shares in the last quarter. Chicago Partners Investment Group LLC lifted its holdings in shares of MannKind by 22.1% in the first quarter. Chicago Partners Investment Group LLC now owns 42,691 shares of the biopharmaceutical company’s stock valued at $105,000 after purchasing an additional 7,741 shares in the last quarter. Royal Bank of Canada lifted its holdings in shares of MannKind by 4.8% in the first quarter. Royal Bank of Canada now owns 216,563 shares of the biopharmaceutical company’s stock valued at $531,000 after purchasing an additional 9,951 shares in the last quarter. AdvisorNet Financial Inc bought a new stake in shares of MannKind in the third quarter valued at about $39,000. Finally, Allworth Financial LP lifted its holdings in shares of MannKind by 2,013.4% in the second quarter. Allworth Financial LP now owns 11,074 shares of the biopharmaceutical company’s stock valued at $47,000 after purchasing an additional 10,550 shares in the last quarter. 49.55% of the stock is currently owned by institutional investors.

MannKind Company Profile

(Get Free Report)

MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults. The company's product pipeline also includes Tyvaso DPI (Treprostinil), an inhalation powder for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; MNKD-101, a nebulized formulation of clofazimine, for the treatment of severe chronic and recurrent pulmonary infections, including nontuberculous mycobacterial lung disease; MNKD-201, a dry-powder formulation of nintedanib, for the treatment of idiopathic pulmonary fibrosis (IPF).